Papillary renal cell carcinoma
MONDO:0017884A rare subtype of renal cell carcinoma, arising from the renal tubular epithelium and showing a papillary growth pattern, which typically manifests with hematuria, flank pain, palpable abdominal mass or nonspecific symptoms, such as fatigue, weight loss or fever. Symptoms related to metastatic spread, such as bone pain or persistent cough, are frequently associated since early diagnosis is not common. It is typically multifocal, bilateral, and in most cases sporadic, although different hereditary syndromes, such as Hereditary leiomyoma renal cell carcinoma, Birt-Hogg-DubC) syndrome and Tuberous sclerosis, may predispose to the development of papillary renal cell carcinoma.
Also known as: HPRCC, chromophil carcinoma of kidney, chromophil carcinoma of the kidney, chromophil renal cell carcinoma, papillary (chromophil) renal cell carcinoma, papillary renal cell adenocarcinoma, papillary renal cell cancer, papillary renal cell carcinoma
2804 clinical trials for this condition and its sub-types, 26 tagged with Papillary renal cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Papillary renal cell carcinoma
-
New hope for rare cancers: Triple-Drug attack shows promise
Disease control Recruiting nowThis phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
Mushroom compound targets kidney cancer in dialysis patients
Disease control Recruiting nowThis early-stage trial is testing a drug called orellanine, derived from a mushroom, in 75 people with advanced kidney cancer who are also on dialysis. The drug is given intravenously to see if it is safe and can shrink tumors. All participants have end-stage kidney disease and h…
Phase 1/2 • Sponsor: Oncorena AB • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat kidney tumors
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—can safely shrink or stabilize advanced kidney cancer in people with hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. The dr…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New antibody drug aims to shrink advanced tumors in early trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called JNJ-89862175 in people with advanced solid tumors (lung, kidney, ovarian, or uterine cancers that have spread). The drug is designed to deliver a toxic payload directly to cancer cells. The main goals are to find a safe dos…
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug SIM0505 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug shrinks tumors. About 414 participants will re…
Phase 1 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug combo aims to fight tough kidney cancers
Disease control Recruiting nowThis study tests two drugs—palbociclib (a daily pill) and sasanlimab (a monthly injection)—in people with advanced kidney cancer (clear cell or papillary type). The goal is to see if the combination can shrink tumors or stop them from growing. About 100 adults will take part for …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New PET scan agent could spot kidney cancer more accurately
Diagnosis Recruiting nowThis study tests a new radioactive imaging agent called [18F]RCCB6 for PET/CT scans to see if it can better detect kidney cancer, especially the most common type, clear cell renal cell carcinoma. Researchers will enroll 300 adults with confirmed or suspected kidney cancer. The go…
Phase 2 • Sponsor: RenJi Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
Scientists track Cancer's diet in real time during surgery
Knowledge-focused Recruiting nowThis study looks at how kidney and bladder cancers use nutrients like sugar and fat to grow. Participants receive a harmless nutrient tracer during surgery or biopsy, and researchers collect blood and tissue samples to analyze cancer metabolism. The study does not change standard…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Kidney cancer drugs under the microscope: Real-World data from china
Knowledge-focused Recruiting nowThis study looks back at medical records of 150 Chinese adults with advanced papillary kidney cancer who were treated with sunitinib or sorafenib. Researchers want to see how long the cancer stays under control and how safe the drugs are in everyday practice. It is an observation…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC